Abstract 2036
Background
As the worldwide prevalence of colorectal cancer (CRC) is increasing, it is of vital importance to reduce its morbidity and mortality by early detection. Saliva is a noninvasively accessible fluid that potentially reflects both oral and systemic diseases. We report here the investigation and validation of salivary biomarkers to distinguish patients with CRC from those with polyps and healthy controls.
Methods
Saliva samples from subjects with CRC, polyps, and healthy controls were collected after 9 hours of fasting, and were split into training and validation data. Capillary electrophoresis-mass spectrometry-based metabolomics was used to quantify numerous hydrophilic metabolites.
Results
A total of 2,602 unstimulated saliva samples were collected from 231 subjects with CRC, 99 subjects with polyps, and 2272 subjects with healthy controls. The data were randomly divided into training (n = 1,301) and validation data (n = 1301). Biomarkers for distinguishing subjects with CRC from the others, as well as metabolites that normalize whole saliva concentration were identified. Analysis of these metabolites using machine learning-based artificial intelligence showed a high area under the receiver operating characteristic curve (AUC = 0.876; P < 0.0001) in the training dataset. This combination also showed high AUC values using the validation dataset (AUC = 0.861; P < 0.0001). Saliva samples were also collected multiple times from identical subjects and the robustness of these biomarkers were confirmed.
Conclusions
Combinations of salivary metabolites show high potential as a screening tool for CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hiroshi Kuwabara.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract